KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Equivalents (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Cash & Equivalents for 17 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 39.12% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2025, up 39.12%, and an annual FY2025 reading of $1.3 billion, up 39.12% over the prior year.
  • Cash & Equivalents was $1.3 billion for Q4 2025 at Biomarin Pharmaceutical, up from $1.3 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.3 billion in Q4 2025 and bottomed at $580.1 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $810.1 million, with a median of $735.8 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents tumbled 39.24% in 2021, then surged 85.08% in 2025.
  • Year by year, Cash & Equivalents stood at $587.3 million in 2021, then rose by 23.37% to $724.5 million in 2022, then grew by 4.22% to $755.1 million in 2023, then increased by 24.86% to $942.8 million in 2024, then soared by 39.12% to $1.3 billion in 2025.
  • Business Quant data shows Cash & Equivalents for BMRN at $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.